Compare Cytokinetics Inc (CYTK) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Omnicom Group Inc. — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.78B), while Omnicom Group Inc. trades at $85.74 (market cap $23.22B). The key difference: Omnicom Group Inc. is far larger — about 2.2× Cytokinetics Inc's market cap, and Omnicom Group Inc. pays a 3.78% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | OMC | |
|---|---|---|
Market Cap | $10.78B | $23.22B |
Sector | Technology | Media |
52-Week High | $87.26 | $86.22 |
52-Week Low | $34.31 | $67.27 |
Enterprise Value | $10.88B | $31.30B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Omnicom Group (OMC) trades at $85.24, up 3.31% today, with a bullish technical outlook supported by moving averages and key resistance at $86. Recent Q2 2026 earnings beat estimates with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company maintains a $0.80 quarterly dividend and benefits from post-merger synergies with Interpublic Group.
OMC presents a value opportunity with a low P/S of 0.96 and consensus price target of $107, but high P/E of 230.38 and integration risks post-acquisition warrant caution. Analyst sentiment is mixed with 32% buy ratings, highlighting growth potential against margin pressures and competitive threats in the advertising sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
